DAMONA Pharmaceuticals™
Treat & Prevent Cognitive Deficits across Brain Disorders & During Aging

Learn More

Team

Meet our team.

Publications

Find a list of our most recent publications, providing key background information in the field of cognitive and mood deficits in psychiatric disorders, and highlighting key finding.

News

Find our latest news on development, presence at scientific and business conferences, and others.

DAMONA Pharmaceuticals™ is a preclinical pharma spinoff founded by the Centre for Addiction and Mental Health (CAMH) and Dr. Etienne Sibille. The mission of DAMONA Pharmaceuticals™ is to discover and develop small molecules for the treatment and prevention of cognitive symptoms in depression and other brain disorders.
  • Thomas Prevot

DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer

 DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer 1200 627 Thomas Prevot

TORONTO, June 13, 2023— DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with…

DAMONA’s development highlighted at the University of Toronto

 DAMONA’s development highlighted at the University of Toronto 1000 730 Thomas Prevot

DAMONA Pharmaceuticals was recently highlighted in a news article, prepared by Ben Gane, for the University of Toronto. This article highlights the creation of Damona by CAMH (the Centre of…

DAMONA Pharmaceuticals Raises US$5.5 Million Seed Stage Financing to Advance Lead Molecule Development to Treat Cognitive Deficits Associated with Depression and Diseases of Aging

 DAMONA Pharmaceuticals Raises US$5.5 Million Seed Stage Financing to Advance Lead Molecule Development to Treat Cognitive Deficits Associated with Depression and Diseases of Aging 940 788 Etienne Sibille

DAMONA raises US5.5 Million Seed Stage Financing to Advance Lead Molecule Development to Treat Cognitive Deficits

The Ontario Brain Institute invests $400,000 CAD in DAMONA

 The Ontario Brain Institute invests $400,000 CAD in DAMONA 2023 774 Thomas Prevot

We are delighted to announce that the Ontario Brain Institute (OBI) is investing approximately $400,000 CAD in Damona Pharmaceuticals, to provide support to the company developing treatments for cognitive deficits in depression…

New Research Article: Reduced inhibition in depression impairs stimulus processing in human cortical microcircuits

 New Research Article: Reduced inhibition in depression impairs stimulus processing in human cortical microcircuits 375 375 Thomas Prevot

Through a multicentered collaboration, joining experts from the Centre for Addiction and Mental Health (CAMH) and University Health Network (UHN), Yao and colleagues are presenting this new release, highlighting how…

BBC World News

February 15, 2019

Dr. Etienne Sibille presented key findings on new compounds for cognitive dysfunction in depression and aging, live on BBC News, after the AAAS meeting in Washington D.C.

Start Typing